Analyst Research Report Snapshot

Title:

LIPOXEN - TRIAL PLANS CONFIRMED

Price:

$10.00

Provider:

Edison Investment Research

Date:

05 Nov 2007

Pages:

2

Type:

AcrobatPDF

Companies referenced:

XENX.L

Available for Immediate Download
Summary:

Lipoxen is planning to start trials of its two lead products, ErepoXen and SuliXen, in the first half of 2008, which if successful, will represent the first clinical validation of the company’s technology. Clinical trials are starting later than anticipated because it has taken longer to obtain the commercial-scale PSA (polysialic acid), from its key strategic partner Serum Institute of India (SII). For this reason we are reducing our 2007–2008 forecasts because of the timing of triggering events for payments from partners and potential partners, which are evaluating PSA technology. FOR MORE INFORMATION ON ATTACHED RESEARCH PLEASE CALL 020 7190 1755 OR EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.